Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Acute,Leukemia, Lymphoid

Interventions: Drug: Dasatinib
Drug: prednisone
Drug: cyclophosphamide
Drug: daunorubicin
Drug: vincristine
Drug: cytarabine
Drug: mercaptopurine
Drug: methotrexate
Drug: dexamethasone
Drug: mitoxantrone
Drug: etoposide
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2015-08-14

Last Posted Date: 2022-08-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 30

Registration Number: NCT02523976

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm

Interventions: Drug: Cytarabine
Drug: Asparaginase
Drug: Asparaginase Erwinia chrysanthemi
Drug: Daunorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Drug: Thioguanine

First Posted Date: 2015-08-13

Last Posted Date: 2024-11-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 280

Registration Number: NCT02521493

Locations: 🇨🇦
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada
🇳🇿
Starship Children's Hospital, Grafton, Auckland, New Zealand
🇳🇿
Christchurch Hospital, Christchurch, New Zealand

and more 188 locations

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Phase 2

Terminated

Conditions: Leukemia, B-Cell
Lymphoma, Non-Hodgkin's
Acute Lymphoblastic Leukemia
Leukemia, T-Cell

Interventions: Drug: Dexamethasone
Drug: Panobinostat
Drug: Liposomal vincristine
Drug: Mitoxantrone
Drug: Peg-asparaginase
Drug: Bortezomib
Drug: Intrathecal Triples
Drug: High-dose methotrexate
Drug: 6-Mercaptopurine
Drug: High-dose cytarabine
Drug: Nelarabine
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Clofarabine

First Posted Date: 2015-08-10

Last Posted Date: 2019-04-03

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 3

Registration Number: NCT02518750

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Phase 1

Completed

Conditions: Refractory Solid Tumors
Relapsed Leukemia
Relapsed Solid Tumors
Refractory Leukemia

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2015-07-31

Last Posted Date: 2024-01-12

Lead Sponsor: Stanford University

Target Recruit Count: 4

Registration Number: NCT02512926

Locations: 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Penn State Hershey Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸
Stanford University School of Medicine and Stanford Cancer Institute, Palo Alto, California, United States

and more 5 locations

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Plasma Cell Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Cytarabine
Drug: Etoposide
Drug: Ixazomib Citrate
Drug: Melphalan
Drug: Methotrexate
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Drug: Tacrolimus

First Posted Date: 2015-07-21

Last Posted Date: 2020-11-23

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 11

Registration Number: NCT02504359

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Phase 1

Completed

Conditions: Medulloblastoma
Diffuse Intrinsic Pontine Glioma
Glioblastoma Multiforme
Malignant Brain Tumor
Ependymoma
Gliosarcoma
Glioma
Primary CNS Tumor

Interventions: Drug: Indoximod
Drug: Temozolomide
Drug: Cyclophosphamide
Radiation: Conformal Radiation
Drug: Etoposide

First Posted Date: 2015-07-20

Last Posted Date: 2020-06-04

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 81

Registration Number: NCT02502708

Locations: 🇺🇸
Children's Heathcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 2 locations

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Placebo
Drug: Trilaciclib
Drug: Etoposide

First Posted Date: 2015-07-16

Last Posted Date: 2020-08-21

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 122

Registration Number: NCT02499770

Locations: 🇺🇸
Roswell Park, Buffalo, New York, United States
🇫🇷
CHU de Rennes Hopital Pontchaillou, Rennes, France
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States

and more 37 locations

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neuroendocrine Tumors
Small Cell Carcinoma
Ovarian Epithelial Cancer

Interventions: Drug: Cisplatin
Drug: RRx-001
Drug: Carboplatin
Drug: Etoposide
Drug: Paclitaxel
Drug: Doxil
Drug: Irinotecan
Drug: Nab-Paclitaxel
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Taxane
Drug: Pemetrexed

First Posted Date: 2015-07-03

Last Posted Date: 2022-10-03

Lead Sponsor: EpicentRx, Inc.

Target Recruit Count: 139

Registration Number: NCT02489903

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Baptist Health, Lexington, Kentucky, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 7 locations

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Phase 1

Terminated

Conditions: Burkitt Lymphoma
CD20-Positive Neoplastic Cells Present
Indolent Non-Hodgkin Lymphoma
Refractory Mature B-Cell Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma

Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Drug: Clearing Agent
Drug: Cytarabine
Drug: Etoposide
Radiation: Indium In 111-DOTA-Biotin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Yttrium Y 90-DOTA-Biotin

First Posted Date: 2015-06-26

Last Posted Date: 2020-11-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT02483000

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Phase 1

Conditions: Adult Burkitt Lymphoma
MYC Gene Mutation
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Plasmablastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Therapeutic Hydrocortisone
Drug: Vincristine Sulfate

First Posted Date: 2015-06-25

Last Posted Date: 2022-02-21

Lead Sponsor: Northwestern University

Target Recruit Count: 38

Registration Number: NCT02481310

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy